Methods of identifying active BRM expression-promoting HDAC inhibitors
View Patent ↗The present invention provides screening methods for identifying BRM expression-promoting histone deacetylase (HDAC) inhibitors, diagnostic methods for determining the suitability of treatment of a candidate subject with a BRM expression-promoting HDAC inhibitor, and therapeutic methods for treating cancer cells in a patient with a BRM expression-promoting HDAC inhibitor. The present invention also provides BRG1 and BRM diagnostics, methods for increasing a cancer patient's resistance to viral infection, and methods for determining the suitability of treatment of a candidate subject with a glucocorticoid compound or retinoid compound.
1. A method for identifying an active BRM expression-promoting histone deacetylase inhibitor that does not inactive BRM via acetylation and that specifically inhibits HDAC3 comprising;
a) providing;
i) a candidate histone deacetylase inhibitor; and
ii) at least one cell, wherein said cell exhibits reduced BRM protein or BRM mRNA expression;
b) contacting said cell with said candidate histone deacetylase inhibitor,
c) measuring BRM protein or BRM mRNA expression exhibited by said cell, or measuring CD44 protein or CD44 mRNA expression exhibited by said cell, wherein an increase in said BRM protein expression, BRM mRNA expression, CD44 protein expression, or CD44 mRNA expression exhibited by said cell identifies said candidate histone deacetylase inhibitor as a BRM expression-promoting histone deactylase inhibitor;
d) identifying said candidate histone deacetylase inhibitor as a BRM expression-promoting histone deactylase inhibitor; and
e) determining that said BRM protein expressed after said contacting is active BRM protein capable of forming a functional SWI/SNF complex, thereby indentifying said BRM expression-promoting histone deacytlase inhibitor as an active BRM expression-promoting histone deacetylase inhibitor that does not inactivate BRM via acetylation and that specifically inhibits HDAC3.
2. The method of claim 1 , wherein said cell further exhibits reduced wild-type BRG1 protein or wild-type BRG1 mRNA expression.
3. The method of claim 1 , wherein said cell is a cancer cell.
4. The method of claim 1 , wherein said cancer cell is breast cancer cell or a prostate cancer cell.
5. The method of claim 1 , wherein said determining that said BRM protein expressed after said contacting is active BRM protein capable of forming a functional SWI/SNF complex comprises detecting vimentin protein or mRNA expression.
6. The method of claim 1 , wherein said determining that said BRM protein expressed after said contacting is active BRM protein capable of forming a functional SWI/SNF complex comprises detecting CD44 protein or mRNA expression.
7. The method of claim 1 , wherein said determining that said BRM protein expressed after said contacting is active BRM protein capable of forming a functional SWI/SNF complex comprises detecting PPARgamma protein or mRNA expression.
8. The method of claim 1 , wherein said determining that said BRM protein expressed after said contacting is active BRM protein capable of forming a functional SWI/SNF complex comprises detecting retinoblastoma protein growth inhibition.
9. The method of claim 1 , wherein said determining that said BRM protein expressed after said contacting is active BRM protein capable of forming a functional SWI/SNF complex comprises detecting BRCAlprotein or mRNA expression.
10. The method of claim 1 , wherein said determining that said BRM protein expressed after said contacting is active BRM protein capable of forming a functional SWI/SNF complex comprises detecting Farconi's anemia protein, protein or mRNA expression.
11. The method of claim 1 , wherein said determining that said BRM protein expressed after said contacting is active BRM protein capable of forming a functional SWI/SNF complex comprises detecting Ceacam-1 protein or mRNA expression.
12. The method of claim 1 , wherein said determining that said BRM protein expressed after said contacting is active BRM protein capable of forming a functional SWI/SNF complex comprises detecting Sparc protein or mRNA expression.
13. The method of claim 1 , wherein said determining that said BRM protein expressed after said contacting is active BRM protein capable of forming a functional SWI/SNF complex comprises detecting LBH protein or mRNA expression.
14. The method of claim 1 , wherein said determining that said BRM protein expressed after said contacting is active BRM protein capable of forming a functional SWI/SNF complex comprises detecting p53 protein or mRNA expression.
15. The method of claim 1 , wherein said determining that said BRM protein expressed after said contacting is active BRM protein capable of forming a functional SWI/SNF complex comprises detecting p107 protein or mRNA expression.